Superluminal Medicines announced a major partnership with Eli Lilly valued at up to $1.3 billion that will focus on discovering small molecule therapeutics against G protein-coupled receptors related to cardiometabolic diseases and obesity. Leveraging Superluminal’s AI-driven drug discovery platform integrating machine learning and structural biology, the collaboration aims to tackle difficult GPCR targets with Lilly responsible for advancing and commercializing selected candidates. The deal includes upfront payments, milestones, royalties, and an equity investment. This represents a strategic expansion for Superluminal as it also advances its own program for rare obesity forms.